FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176389231> ?p ?o ?g. }

• W3176389231 endingPage "1360" @default.
• W3176389231 startingPage "1360" @default.
• W3176389231 abstract "Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential of T-DM1 as monotherapy is so far unknown.To assess pathologic complete response (pCR) to standard neoadjuvant therapy of combination docetaxel, trastuzumab, and pertuzumab (DTP) vs T-DM1 monotherapy in patients with ERBB2 (formerly HER2)-positive breast cancer.This randomized phase 2 trial, conducted at 9 sites in Sweden, enrolled 202 patients between December 1, 2014, and October 31, 2018. Participants were 18 years or older, with ERBB2-positive tumors larger than 20 mm and/or verified lymph node metastases. Analysis was performed on an intention-to-treat basis.Patients were randomized to receive 6 cycles of DTP (standard group) or T-DM1 (investigational group). Crossover was recommended at lack of response or occurrence of intolerable toxic effects. Assessment with fluorine 18-labeled fluorodeoxyglucose (18F-FDG) positron emission tomography combined with computed tomography (PET-CT) was performed at baseline and after 2 and 6 treatment cycles.Pathologic complete response, defined as ypT0 or Tis ypN0. Secondary end points were clinical and radiologic objective response; event-free survival, invasive disease-free survival, distant disease-free survival, and overall survival; safety; health-related quality of life (HRQoL); functional and biological tumor characteristics; and frequency of breast-conserving surgery.Overall, 202 patients were randomized; 197 (99 women in the standard group [median age, 51 years (range, 26-73 years)] and 98 women in the investigational group [median age, 53 years (range, 28-74 years)]) were evaluable for the primary end point. Pathologic complete response was achieved in 45 patients in the standard group (45.5%; 95% CI 35.4%-55.8%) and 43 patients in the investigational group (43.9%; 95% CI 33.9%-54.3%). The difference was not statistically significant (P = .82). In a subgroup analysis, the pCR rate was higher in hormone receptor-negative tumors than in hormone receptor-positive tumors in both treatment groups (45 of 72 [62.5%] vs 45 of 125 [36.0%]). Three patients in the T-DM1 group experienced progression during therapy. In an exploratory analysis, tumor-infiltrating lymphocytes at 10% or more (median) estimated pCR significantly (odds ratio, 2.76; 95% CI, 1.42-5.36; P = .003). Response evaluation with 18F-FDG PET-CT revealed a relative decrease of maximum standardized uptake value by equal to or greater than 68.7% (median) was associated with pCR (odds ratio, 6.74, 95% CI, 2.75-16.51; P < .001).In this study, treatment with standard neoadjuvant combination DTP was equal to T-DM1.ClinicalTrials.gov Identifier: NCT02568839; EudraCT number: 2014-000808-10." @default.
• W3176389231 created "2021-07-05" @default.
• W3176389231 creator A5004016779 @default.
• W3176389231 creator A5008654654 @default.
• W3176389231 creator A5021304141 @default.
• W3176389231 creator A5021395985 @default.
• W3176389231 creator A5024622557 @default.
• W3176389231 creator A5025336524 @default.
• W3176389231 creator A5026436902 @default.
• W3176389231 creator A5030530591 @default.
• W3176389231 creator A5031545628 @default.
• W3176389231 creator A5037407272 @default.
• W3176389231 creator A5040974297 @default.
• W3176389231 creator A5041876892 @default.
• W3176389231 creator A5043700235 @default.
• W3176389231 creator A5051110265 @default.
• W3176389231 creator A5052651212 @default.
• W3176389231 creator A5057126644 @default.
• W3176389231 creator A5064558241 @default.
• W3176389231 creator A5065384975 @default.
• W3176389231 creator A5065433718 @default.
• W3176389231 creator A5071571360 @default.
• W3176389231 creator A5075557023 @default.
• W3176389231 creator A5076091991 @default.
• W3176389231 creator A5076773519 @default.
• W3176389231 creator A5078789108 @default.
• W3176389231 creator A5082110835 @default.
• W3176389231 creator A5090648376 @default.
• W3176389231 date "2021-09-01" @default.
• W3176389231 modified "2023-10-02" @default.
• W3176389231 title "Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer" @default.
• W3176389231 cites W1848007259 @default.
• W3176389231 cites W1906753921 @default.
• W3176389231 cites W2038312994 @default.
• W3176389231 cites W2075894019 @default.
• W3176389231 cites W2095861620 @default.
• W3176389231 cites W2104399141 @default.
• W3176389231 cites W2120431466 @default.
• W3176389231 cites W2123591186 @default.
• W3176389231 cites W2136775492 @default.
• W3176389231 cites W2167571044 @default.
• W3176389231 cites W2283816551 @default.
• W3176389231 cites W2605135450 @default.
• W3176389231 cites W2768649895 @default.
• W3176389231 cites W2809293192 @default.
• W3176389231 cites W2899659781 @default.
• W3176389231 cites W2902218997 @default.
• W3176389231 cites W2914243257 @default.
• W3176389231 cites W2937568369 @default.
• W3176389231 cites W2948405934 @default.
• W3176389231 cites W4251210156 @default.
• W3176389231 cites W4254815115 @default.
• W3176389231 cites W4292528167 @default.
• W3176389231 doi "https://doi.org/10.1001/jamaoncol.2021.1932" @default.
• W3176389231 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8227457" @default.
• W3176389231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34165503" @default.
• W3176389231 hasPublicationYear "2021" @default.
• W3176389231 type Work @default.
• W3176389231 sameAs 3176389231 @default.
• W3176389231 citedByCount "21" @default.
• W3176389231 countsByYear W31763892312021 @default.
• W3176389231 countsByYear W31763892312022 @default.
• W3176389231 countsByYear W31763892312023 @default.
• W3176389231 crossrefType "journal-article" @default.
• W3176389231 hasAuthorship W3176389231A5004016779 @default.
• W3176389231 hasAuthorship W3176389231A5008654654 @default.
• W3176389231 hasAuthorship W3176389231A5021304141 @default.
• W3176389231 hasAuthorship W3176389231A5021395985 @default.
• W3176389231 hasAuthorship W3176389231A5024622557 @default.
• W3176389231 hasAuthorship W3176389231A5025336524 @default.
• W3176389231 hasAuthorship W3176389231A5026436902 @default.
• W3176389231 hasAuthorship W3176389231A5030530591 @default.
• W3176389231 hasAuthorship W3176389231A5031545628 @default.
• W3176389231 hasAuthorship W3176389231A5037407272 @default.
• W3176389231 hasAuthorship W3176389231A5040974297 @default.
• W3176389231 hasAuthorship W3176389231A5041876892 @default.
• W3176389231 hasAuthorship W3176389231A5043700235 @default.
• W3176389231 hasAuthorship W3176389231A5051110265 @default.
• W3176389231 hasAuthorship W3176389231A5052651212 @default.
• W3176389231 hasAuthorship W3176389231A5057126644 @default.
• W3176389231 hasAuthorship W3176389231A5064558241 @default.
• W3176389231 hasAuthorship W3176389231A5065384975 @default.
• W3176389231 hasAuthorship W3176389231A5065433718 @default.
• W3176389231 hasAuthorship W3176389231A5071571360 @default.
• W3176389231 hasAuthorship W3176389231A5075557023 @default.
• W3176389231 hasAuthorship W3176389231A5076091991 @default.
• W3176389231 hasAuthorship W3176389231A5076773519 @default.
• W3176389231 hasAuthorship W3176389231A5078789108 @default.
• W3176389231 hasAuthorship W3176389231A5082110835 @default.
• W3176389231 hasAuthorship W3176389231A5090648376 @default.
• W3176389231 hasBestOaLocation W31763892311 @default.
• W3176389231 hasConcept C121608353 @default.
• W3176389231 hasConcept C126322002 @default.
• W3176389231 hasConcept C141071460 @default.
• W3176389231 hasConcept C143998085 @default.
• W3176389231 hasConcept C168563851 @default.
• W3176389231 hasConcept C2777511904 @default.
• W3176389231 hasConcept C2778087150 @default.

• next